Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
131 participants
OBSERVATIONAL
2010-03-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* identification of factors predisposing for Post-Infectious Irritable Bowel Syndrome (PI-IBS) development after an episode of traveler's diarrhea
* identification of systemic (serum) and local (biopsy) changes in infectious and immunological activity during infection and correlation with Irritable Bowel Syndrome (IBS) symptoms, persisting after traveler's diarrhea
Design:
* 4 study visits: before traveling, 2 weeks after traveling, 6 months after traveling, 12 months after traveling
* at each study visit following investigations: blood collection, stool collection, questionnaires, rectal biopsy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating
NCT02299973
ConfocAl endomicroSCopy bAsed Diet Trial in IBS
NCT05097872
Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
NCT01787253
The Effect of a Low FODMAP Diet in Irritable Bowel Syndrome Patients
NCT04373304
Efficacy of the DOMINO Diet App in IBS
NCT05808036
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
travelers to tropical destinations
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-70 years
* traveling for 1-10 weeks
Exclusion Criteria
* Pregnant
* Colitis Ulcerosa
* Morbus Chrohn
* IBS
* Coeliakie
* Gastrointestinal malabsorption
* microscopic colitis
* diverticulitis
* immune deficiency
* use of antibiotics/corticosteroids 2 weeks before travelling
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guy Boeckxstaens
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guy Boeckxstaens, M.D.
Role: PRINCIPAL_INVESTIGATOR
Catholic University Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University hospitals Leuven
Leuven, Vlaams-Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wouters MM, Van Wanrooy S, Nguyen A, Dooley J, Aguilera-Lizarraga J, Van Brabant W, Garcia-Perez JE, Van Oudenhove L, Van Ranst M, Verhaegen J, Liston A, Boeckxstaens G. Psychological comorbidity increases the risk for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Gut. 2016 Aug;65(8):1279-88. doi: 10.1136/gutjnl-2015-309460. Epub 2015 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S51501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.